More than 900 Australian and global life science leaders are uniting virtually this week to celebrate, champion, and further the sector at AusBiotech 2021 and Australia Biotech Invest and Partnering 2021, the country's premier life science conferences that commenced today.
Australia’s biggest week in biotech features the events of the year that the sector has known and trusted for over 35 years, and attracts industry leaders, investors, researchers and regulatory and government representatives.
The two conferences will lift the profile of the Australian biotechnology industry, share new and ground-breaking knowledge, connect companies, and create access to greater funding sources for companies to develop world-class science into therapies, diagnostics and medical devices.
The AusBiotech 2021 programme has been developed by industry for industry; online and on-demand, the five days are packed with more than 100 inspiring thought leaders from across 25 countries, in almost 30 sessions. Delegates will be engaging, their way, as they pitch, partner, exchange ideas and remain engaged with our national and international biotech community.
Australia Biotech Invest & Partnering 2021 remains the preeminent opportunity for companies to present their technology and story to a network of potential international partners and investors. The full-day programme features five keynote speakers and over 20 public and private companies, showcasing the potential of life sciences.
The ‘foundation stones’ for Australia’s regenerative medicine (RM) future will be complete, with the publication of three resources offering new knowledge and benchmarking, purpose, and a firm, unified direction for the industry’s future, during the AusBiotech 2021 Catalysing regenerative medicine in Australia panel discussion today.
Benchmarking the investment in the sector in Australia in 2019 and 2020, Australia’s Regenerative Medicine Investments Database reveals the extent of private funding and active interest that has been invested into the sector. Investment increased by 113 per cent between 2019 and 2020, and with $394.1 million invested into RM in 2020, this accounts for approximately 23 per cent of the overall capital invested into the Australian biotech sector. The group of four case studies demonstrates the breadth of cell and gene technology development present in Australia and its potential for addressing and managing patients’ unmet needs, and the Strategic Roadmap for the Regenerative Medicine Sector is charting the way ahead with priorities identified to support the sector’s growth.
The Regenerative Medicine Consortium will deliver the final ‘capstones’ in its 12-month project, and collectively, these demonstrate the breadth of opportunity present in the Australian RM sector.
AusBiotech 2021 and Australia Biotech Invest & Partnering 2021 are proudly supported by their Host State Partner, the Victorian Government.
Registrations remain open, and the programmes are available on demand throughout November.